BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options

Yan Zhu; Zhechun Ding; Yini Wang; Qing Wu; Dongmei Chen; Luanhong Wang; Yuancheng Li; Yao Yao; Jiman Huang; Yun Li; Xiaojing Wang; Yanchun Lin; Tian Guan; Haoyu Zeng; Congzhu Li

doi:10.3389/fonc.2023.1239957

BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options

Front Oncol. 2023 Dec 15:13:1239957. doi: 10.3389/fonc.2023.1239957. eCollection 2023.

Authors

Yan Zhu^#¹, Zhechun Ding^#², Yini Wang¹, Qing Wu¹, Dongmei Chen², Luanhong Wang¹, Yuancheng Li¹, Yao Yao², Jiman Huang², Yun Li², Xiaojing Wang¹, Yanchun Lin², Tian Guan², Haoyu Zeng², Congzhu Li¹

Affiliations

¹ Department of Gynecological Oncology, Tumor Hospital Affiliated to Medical College of Shantou University, Shantou, China.
² Department of Cancer Research, Guangdong Procapzoom Biosciences, Inc., Guangzhou, Guangdong, China.

^# Contributed equally.

Abstract

Introduction: In cancer treatment, every minute counts. Due to the unpredictable behavior of cancer cells caused by continuous mutations, each cancer patient has a unique situation and may or may not respond to a specific drug or treatment. The process of finding an effective therapy can be time-consuming, but cancer patients do not have the luxury of time for trial and error. Therefore, a novel technology to fast generate a patient relevant organoid for the therapies selecting is urgently needed.

Methods: Utilizing the new organoid technology by specially dissolving the mesenchyme in tumor tissues acquired from cancer patients, we realized the work of creating patient-specific organoids (PSO) within one day.

Results: PSO properties reflect those of its respective original in vivo tumor tissue and can be utilized to perform various in vitro drug sensitivity tests to identify the most effective clinical treatment for patients. Additionally, PSO can aid in assessing the efficacy of immune cell therapies.

Discussion: Organoid technology has advanced significantly in recent years. However, current cancer organoid methods involve creating 3D tumor tissue from 2D cancer cells or cell clusters, primarily for cancer research purposes aimed at investigating related molecular and cellular mechanisms of tumor development. These methods are research-driven, not tailored towards clinical applications, and cannot provide personalized information for individual patients. PSO filled the gap of clinic-driven and time-saving method for the personalized therapies selecting to the cancer patients.

Keywords: gynecologic cancer; organoid; patient specific; personalized treatment; tumor.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the grants from Medical and Health Public Welfare Foundation of Beijing, China (Grant Nos. YWJKJJHKYJJ-F3164C), and Beijing Xisike Clinical Oncology Research Foundation, China (Grant Nos. Y-tongshu2021/ms-0294), and supported by Guangdong Basic and Applied Basic Research Foundation, China (Grant Nos. 2022A1515220216).